Navigation Links
Vioxx Settlement Announced
Date:11/9/2007

TAMPA, Fla., Nov. 9 /PRNewswire/ -- After several years of litigation, Merck has agreed to pay $4.85 billion in a settlement over Vioxx. The medication was pulled off the market in 2004 after a clinical trial proved it increased the risks of heart attacks and strokes. It is one of the largest pharmaceutical settlements in history.

James Hoyer Newcomer and Smiljanich is pleased this long process is coming to a resolution. The firm has more than a dozen clients who've suffered the ill-effects of taking Vioxx. "This settlement was a long time coming, but one that will finally give our clients some relief from the harm they suffered," said Attorney John Newcomer.

Nearly 30-thousand lawsuits have been filed nationwide against Merck because of Vioxx. Plaintiffs will receive different settlement payments depending on the severity of their injuries and the length of time they took Vioxx. Plaintiff Alvin Jupiter, of Tampa, suffered a heart attack in 2001 after taking Vioxx. He said, "I'm glad to see something coming to fruition on this. So many people were hurt."

James Hoyer Newcomer & Smiljanich will review details of the settlement over the coming weeks and work to ensure our clients are compensated fairly.


'/>"/>
SOURCE James Hoyer Newcomer & Smiljanich
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. New study may explain Vioxx side-effects
2. Study Points to Cause of Vioxx Heart Risk
3. Vioxx Ban Tied to Rise in Serious GI Trouble
4. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
5. Vioxx Settlement Puts Painkillers Back in the Spotlight
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
8. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
9. $52.5 Million Settlement Against Sepracor Inc. Approved
10. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
11. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications collaborated ... Prevention,” an animated video designed to prevent the next widespread Ebola ... video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and ...
(Date:2/9/2016)... FL (PRWEB) , ... February 09, 2016 , ... Shark Finds and Kevin ... new DRTV campaign with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved ... who play in the wet and early morning dew or right after a rain shower, ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... launched its newly redesigned website, federallabs.org . The site houses a wealth ... license available federal technologies through the process called technology transfer (T2). As a ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, serving ... a new charity campaign. As part of their ongoing community involvement program, funds ... belief that children deserve a voice, and in the spirit of neighbors helping ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... BantamPro L top-load case packer for pouches, bags, and flow wrapped products at ... help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic case ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... ORLANDO, Florida , February 9, 2016 /PRNewswire/ ... QIA) today announced a collaboration with 10x Genomics ... sequencing (NGS), single-cell biology and bioinformatics. --> ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QIAGEN ...
(Date:2/9/2016)... -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a ... and heart failure, today announced that it intends to offer ... in an underwritten public offering.  The offering is subject to ... as to whether or when the offering may be completed, ... offering.   --> --> ...
Breaking Medicine Technology: